Furthermore, IL-23 inhibitors appear effective and safe in special populations, including patients with concurrent inflammatory bowel disease, obesity, or advanced age (Blauvelt et al., 2023). The gene discussed is IL23A; the disease is obesity due to melanocortin 4 receptor deficiency.